-
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
July 13, 2026 20:35 ET | Source: Mesoblast Limited NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L…
-
GNI Group Completes Acquisition of AYUMI Pharmaceutical
TOKYO, July 01, 2026 (GLOBE NEWSWIRE) — GNI Group Ltd. (TSE: 2160, “GNI Group” or the “Company”) today announced that it has completed the acquisition of all shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone. As a result, Ayumi Pharmaceutical Holdings Co., Ltd. and its subsidiary, Ayumi Pharmaceutical Co., Ltd. (“Ayumi…
-
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study Sanofi intends to submit the data to support a regulatory application in the…
-
AiraBreeze Announces Entry into the Portable Cooling Products Industry with Introduction of Its First Consumer Cooling Solution
London, UK, June 28, 2026 (GLOBE NEWSWIRE) — AiraBreeze today announced its entry into the portable cooling products industry through the introduction of its first consumer cooling solution following the completion of its initial product development phase. The announcement marks the company’s transition from product design and development into commercial operations as it begins offering…
-
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1 HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and…
-
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – June 23, 2026 14:00 ET | Source: Coherus Oncology, Inc. REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech…
-
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than those observed in trials of competing agents at the end of their respective parental trials Namely, ~67% of patients treated with SLK…
-
THE POWER OF PLAY: NEW RESEARCH CONFIRMS JUST SECONDS OF PLAY INSTANTLY BRING FAMILIES CLOSER
Findings from Phase 2 of the “Power of Play: Family Connection” study from Kinder and the University of East London (UEL) confirm that shared play is a powerful catalyst for strengthening emotional and physical connection between parents and children. To further support families and kids in playtime, Kinder has expanded its Value of Play hub…
-
NIANCE Expands Beyond Products into a Global Beauty & Longevity Ecosystem
ZURICH, June 3, 2026 /PRNewswire/ — Swiss luxury beauty brand NIANCE is entering a new phase of growth with the launch of an integrated beauty and longevity ecosystem combining skincare, supplementation, diagnostics, treatments, recovery, and wellness experiences. Known for its science-backed approach to healthy aging, NIANCE has spent the past decade developing products to support beauty…
-
India's Sporting Future Will Be Built at League Level: Nicole Junkermann
India does not need to be told it is a major sports market. It already is. The bigger question now is how the next phase of growth is going to be built. According to Nicole Junkermann, founder of Gameday by NJF Holdings, the most significant long-term opportunities may lie beyond individual teams and headline…
-
Maverick Investments and Henox Announce Phased Development of 100 MW Green Data Centre and Cable Landing Station in Tamil Nadu
Initial Rs. 200 crore equity approved by Siraj Holdings with a structured platform being prepared to mobilise up to Rs. 50,000 crore over the project lifecycle Singapore | Chennai, India Maverick Investments Limited, part of the UAE-based Siraj Holdings Group, and Henox IT and Data Centers today outlined the first phase of Project Horizon, a…
-
Platinum Industries Announces Entry into Life Sciences; Collaborates with Dr. Abhigyan Upadhyay to Lead the New Enterprise, Rivadu Lifesciences Pvt. Ltd.
Strengthens leadership to build a research-driven and globally scalable model in high-value life sciences segments Mumbai, Maharashtra, India Platinum Industries Ltd. [NSE: PLATIND; BSE: 544134], an innovation-driven specialty chemicals company announced its strategic entry into the life sciences sector, marking a significant step in its next phase of growth. As part of this expansion, the…
-
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
